Phaseline

Companies › ImmVirx

ImmVirx: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Jun 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
IVX037
Oncolytic RNA virus
–Phase 1Colorectal CancerJun 2028
Sintilimab
Programmed cell death protein 1 antagonist
PDCD1Phase 1Colorectal CancerJun 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05427487IVX037Phase 1Colorectal CancerOncologyJun 2028
NCT05427487SintilimabPhase 1Colorectal CancerOncologyJun 2028

Targets

PDCD1 (1)

Companies with the same targets

Akeso Sichuan Baili Pharmaceutical Innovent Biologics (Suzhou) Shanghai Henlius Biotech AstraZeneca Shenyang Sunshine Pharmaceutical Regeneron Pharmaceuticals Ono Pharmaceutical Mabwell (Shanghai) Bioscience Johnson & Johnson (Janssen)

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.